Intrahepatic Cholangiocarcinoma Clinical Trial
Official title:
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
This research study is evaluating a drug called cabozantinib as a possible treatment cancer
of the bile duct. Cabozantinib is a drug that targets specific pathways inside the cells of
the body. By blocking the c-MET and VEGFR2 pathways from sending signals, cabozantinib may
prevent cells from multiplying. This drug has been used in other research studies and
information from those other research studies suggests that this drug may help to stop the
growth of bile duct cancer.
In this research study, the investigators are looking to see how well cabozantinib works in
slowing the growth of bile duct cancer. The investigators are also assessing the safety and
tolerability of cabozantinib in participants with this type of cancer.
After the screening procedures confirm that the participants are eligible to participate in
the research study:
A two-stage design will be employed in this study where at least 9 of the 20 patients
enrolled in the first stage need to be progression-free at 16 weeks before the second stage
can proceed. If this criterion is met, an additional 24 patients will be enrolled in the
second stage for a total of 44 patients in the study. Patients will be treated with
cabozantinib 60 mg daily administered orally continuously for 28-day cycles. Tumor
assessments will be performed every 8 weeks until documented disease progression by RECIST
criteria or drug intolerance.
In this research study, the participant will be given a study drug-dosing diary for each
treatment cycle. Each treatment cycle lasts 28 days (4 weeks), during which time the
participant will be taking the study drug, cabozantinib daily. The diary will also include
special instructions for taking the study drug(s).
The participant will continue to take cabozantinib for as long as it is tolerated without
any unacceptable side effects and the cancer does not get worse.
The following tests and procedures will be done during the research study:
Cycle 1 - On days 1, 8 and 15
- Medical History
- Physical Exam including vital signs and height and weight
- Performance Status
- Review of side effects (day 8 and 15 only)
- Routine blood tests (day 8 and 15 only)
- TSH blood sample on day 1 only
Additional research procedures during Cycle 1:
- Biomarker blood sample (about 2 teaspoons of blood) on day 3 and day 14
Cycles 2-3 - On days 1 and 15
- Medical History
- Physical Exam including vital signs, height and weight
- Performance Status
- Review of side effects
- EKG - day 1 of each cycle ONLY
- Routine blood tests
- Urine test on Day 1 of each cycle ONLY
- Urine pregnancy test on day 1 of each cycle for women of childbearing potential
- TSH blood sample on day 1 only
Cycle 4 and Beyond: Day 1 ONLY
- Medical History
- Physical Exam including vital signs, height and weight
- Performance Status
- Review of side effects
- EKG
- Routine blood tests
- TSH blood sample on day 1 only
- Urine test
- Urine pregnancy test for women of childbearing potential
The following tests will be done every 2 cycles during the research study:
- CA 19-9 blood sample
- Tumor measurements
- Chest/Abdominal/Pelvic CT/MRI of your tumor
Planned Follow-up:
The participant will return to the clinic between 30-37 days after the last dose of
cabozantinib for the following tests and procedures:
- Medical History
- Physical Exam including vital signs, height and weight
- Performance Status
- Review of side effects
- Routine blood tests
- CA 19-9 blood sample
- TSH blood sample
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05678218 -
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
|
||
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Completed |
NCT01938729 -
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
|
Phase 1 | |
Completed |
NCT03230318 -
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT06239532 -
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05535647 -
Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Not yet recruiting |
NCT05009953 -
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
Terminated |
NCT02254681 -
Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC
|
Phase 2 | |
Completed |
NCT01347333 -
Stereotactic Body Radiotherapy for Liver Tumors
|
N/A | |
Active, not recruiting |
NCT04526106 -
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05285358 -
Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
|
Phase 1 | |
Completed |
NCT03320980 -
RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma
|
N/A | |
Withdrawn |
NCT05019677 -
GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC
|
Phase 2 | |
Withdrawn |
NCT03801499 -
Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
|
Phase 2 | |
Completed |
NCT05489692 -
HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
|
||
Recruiting |
NCT06101277 -
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
|
N/A | |
Active, not recruiting |
NCT01917370 -
VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway
|
N/A | |
Withdrawn |
NCT01775280 -
Response of Hepatic Tumors to Radioembolization
|
Phase 2 | |
Not yet recruiting |
NCT05342194 -
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
|
Phase 3 | |
Active, not recruiting |
NCT05781958 -
Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC
|
Phase 2 |